<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02312401</url>
  </required_header>
  <id_info>
    <org_study_id>14-172</org_study_id>
    <nct_id>NCT02312401</nct_id>
  </id_info>
  <brief_title>Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy</brief_title>
  <official_title>Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand prostate cancer changes after radiation
      treatment, through magnetic resonance imaging (MRI). MRI is an imaging test that allows
      doctors to see prostate gland without any operation procedures. It can help identifying the
      tumors in the prostate. For patients with newly diagnosed prostate cancer, MRI may help
      doctors manage treatment better and sooner.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>characterize the changes in tumor characteristics by functional imaging changes with post-treatment prostate biopsy outcomes</measure>
    <time_frame>at 24 months after completion of radiotherapy</time_frame>
    <description>This change will then be correlated with the biopsy outcome (binary) by two sample t-tests.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Multiparametric MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 &amp; 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>multi-parametric MRI(MP-MRI)</intervention_name>
    <arm_group_label>Multiparametric MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>dynamic contrast-enhanced MRI (DCE)</intervention_name>
    <arm_group_label>Multiparametric MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <arm_group_label>Multiparametric MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biopsy proven (completed and/or reviewed at MSK) adenocarcinoma of the
             prostate, who will undergo external beam radiotherapy using conventional fractionation
             IGRT including moderate hypofractionated radiation, low rate brachytherapy alone, low
             dose brachytherapy combined with supplemental image guided radiation (including IGRT,
             EBRT, and SBRT), SBRT, or proton radiotherapy.

          -  Age â‰¥ 18 years old

          -  Baseline MP-MRI, which is obtained at MSKCC Main Campus on the 3-Tesla Philips MRI
             unit as part of the standard (clinical) staging assessment demonstrates at least one
             dominant or visible lesion which measures &gt; 0.5 cm in maximum axial diameter as
             assessed on T2-weighted images.

          -  No prior history of androgen deprivation therapy within the last month. However
             patients who will receive neoadjuvant and concurrent and adjuvant hormonal therapy
             will be eligible.

          -  Willing to come to MSK Main Campus for baseline and follow-up MP-MRIs.

        Exclusion Criteria:

          -  History of radical prostatectomy

          -  Patients who are unwilling or unable to undergo MRI including patients with
             contraindications to MRI such as the presence of cardiac pacemakers or non-compatible
             intracranial vascular clips, claustrophobia, inability to lie flat for the duration of
             the study etc.

          -  Patients with a metallic hip implant, metallic implant or device in the pelvis or
             ferromagnetic fiducial beacons (Calypso) that might distort local magnetic field and
             compromise quality of MP-MRI

          -  Patients in which gadolinium contrast is contra-indicated.

          -  Metastatic disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zelefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Zelefsky, MD</last_name>
    <phone>212-639-6802</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hebert A. Vargas, MD</last_name>
    <phone>212-639-4017</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
    <investigator>
      <last_name>Michael Zelefsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2014</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>14-172</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

